Grail Shares Surge 30% As FDA Reviews Cancer-Detecting Blood Test
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Grail stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday.
Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.
Grail
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Grail stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday.”
IBD — Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test“Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.”
stat news — STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators